These data are consistent with the results presented here; that 3-copies of Cstb (as occurs in the DS patient fibroblasts preclinical model used in Jiang et al. 2019) are not sufficient to markedly change cathepsin B activity. The gene discussed is CTSB; the disease is Dravet syndrome.